The effects of non-surgical periodontal treatment on glycemic control, oxidative stress balance and quality of life in patients with type 2 diabetes: A randomized clinical trial

Hirofumi Mizuno1, Daisuke Ekuni1,2*, Takayuki Maruyama3, Kota Kataoka1, Toshiki Yoneda1, Daiki Fukuhara1, Yoshio Sugita1, Takaaki Tomofuji4, Jun Wada5, Manabu Morita1

1 Department of Preventive Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2 Advanced Research Center for Oral and Craniofacial Sciences, Okayama University Dental School, Okayama, Japan, 3 Center for Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan, 4 Department of Community Oral Health, Asahi University School of Dentistry, Mizuho, Japan, 5 Department of Nephrology, Rheumatology, Endocrinology, and Metabolism, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

* dekuni7@md.okayama-u.ac.jp

Abstract

Aim
The purpose of this study was to investigate the effects of non-surgical periodontal treatment on hemoglobinA1c (HbA1c) levels, oxidative stress balance and quality of life (QOL) in patients with type 2 diabetes mellitus (T2DM) compared to no periodontal treatment (simple oral hygiene instructions only).

Methods
The design was a 6-month, single-masked, single center, randomized clinical trial. Patients had both T2DM and chronic periodontitis. Forty participants were enrolled between April 2014 and March 2016 at the Nephrology, Diabetology and Endocrinology Department of Okayama University Hospital. The periodontal treatment group (n = 20) received non-surgical periodontal therapy, including scaling and root planing plus oral hygiene instructions, and consecutive supportive periodontal therapy at 3 and 6 months. The control group (n = 17) received only oral hygiene instructions without treatment during the experimental period. The primary study outcome was the change in HbA1c levels from baseline to 3 months. Secondary outcomes included changes in oxidative stress balance (Oxidative-INDEX), the Diabetes Therapy-Related QOL and clinical periodontal parameters from baseline to 3 months and baseline to 6 months.
Results
Changes in HbA1c in the periodontal treatment group were not significantly different with those in the control group at 3 and 6 months. Systemic oxidative stress balance and QOL significantly improved in the periodontal treatment group compared to the control group at 3 months. In the subgroup analysis (moderately poor control of diabetes), the decrease in HbA1c levels in the periodontal treatment group was greater than that in the control group at 3 months but not significant.

Conclusions
In T2DM patients, non-surgical periodontal treatment improved systemic oxidative stress balance and QOL, but did not decrease HbA1c levels at 3 months follow-up.

Trial registration
Current Controlled Trials UMIN-ICDR UMIN 000013278 (Registered April 1, 2014).

Introduction
Type 2 diabetes mellitus (T2DM) is a common chronic disease and can cause various health issues. Treatment goals include the prevention of complications as well as glycemic control [1]. A position statement by the Diabetes Association in 2016 [2] also suggests that a complete medical evaluation should be performed to detect diabetes complications.

Periodontitis and diabetes are chronic diseases with an established bidirectional relationship. Periodontitis is recognized as the sixth complication of diabetes [3] and is a major cause of tooth loss in adults [4]. Recent reviews suggest that periodontitis adversely affects diabetes outcomes. The effect of periodontitis on diabetes may be explained by the increase in levels of systemic proinflammatory mediators, which exacerbates insulin resistance [5]. However, evidence for treatment benefits remains controversial due to the variety of the sample population, methods and control of T2DM [2, 6–14].

Recent studies suggest that oxidative stress plays an important role in the pathophysiology of both T2DM and periodontitis [15–25]. We previously showed that non-surgical periodontal treatment (scaling and root planing and supportive periodontal therapy) reduced systemic oxidative stress in healthy patients [26]. Thus, the periodontal treatment may also improve oxidative stress in T2DM patients.

The complications of diabetes significantly impair quality of life (QOL) [27–31], and the reduction in QOL may interfere with diabetes treatment. Thus, improvement of these complications may contribute to better QOL for diabetes patients. Although recent reviews suggest that outcome measures in clinical trials should include QOL, there are no studies focusing on the effects of periodontal treatment on QOL [9, 32]. Therefore, we hypothesized that non-surgical periodontal treatment reduces systemic oxidative stress and HbA1c levels as well as improves QOL in T2DM patients. The purpose of this randomized clinical trial was to investigate the effects of non-surgical periodontal treatment on HbA1c levels, oxidative stress and QOL in patients with T2DM and periodontitis compared to no periodontal treatment.
Materials and methods

Trial design

The trial was a single-masked, parallel-design, single center, randomized clinical trial that enrolled participants from outpatient medical and dental clinics in Japan following the CONSORT guidelines. The study protocol was approved by the Ethics Committee, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences and Okayama University Hospital (no. d11004). Physicians enrolled the participants during the diabetes care visits. All patients provided written informed consent. An independent center reviewed the safety data throughout the trial. Code breaking was performed after the final statistical analysis. Before and after the trial, there were no changes in eligibility criteria and outcomes.

Randomization

Randomization was stratified by levels of HbA1c (< 8% vs. ≥ 8%), insulin (use vs. no use) and the number of medications (≤ 2 vs. >2). Each selected patient received a code number and one of the study coordinators (T.M.) used a computer-generated table to randomly allocate patients to one of the two groups (control and periodontal treatment group as below) (allocation ratio; 1:1) [33].

Blinding

Study personnel, including the periodontal examiners, laboratory personnel who performed the HbA1c analyses and the investigator responsible for the data analysis were blinded to the treatment assignment.

Participants

Participants were recruited between April 2014 and March 2016 at the Nephrology, Diabetology and Endocrinology Department of Okayama University Hospital. The inclusion criteria (see below) were selected to maximize the chance that a participant would complete the 6-month trial. Men and women (≥ 30 years) were eligible if they had physician-diagnosed T2DM (diagnosed at least 2 months prior to the study), reported that they were able to make hospital visits throughout the trial, were in the care of a physician for their diabetes, and agreed to not change their diabetes medications during the trial unless medically indicated. Patients also required a diagnosis of mild to advanced chronic periodontitis, defined as ≥ 2 interproximal sites with clinical attachment level (CAL) ≥ 3 mm and ≥ 2 interproximal sites with probing pocket depth (PPD) ≥ 4 mm (not on the same tooth) or one site with PPD ≥ 5 mm [34]. Radiographs were used to confirm a diagnosis of chronic periodontitis [35]. Exclusion criteria included pregnancy, inappropriate status for the trials, such as limited life expectancy and diabetes-related emergency, and receiving periodontal treatment in the prior 6 months [35].

Intervention

Initially, all participants received one session of supra-gingival plaque removal and oral hygiene instructions. The patients of the periodontal group were treated by a protocol adapted from the Japanese Society of Periodontology. The non-surgical periodontal treatment consisted of at least 60 minutes of scaling and root planing using curettes (BioGent Curette, Hu-Friedy, Chicago, IL, USA; Scaler YB, YDM Corporation, Saitama, Japan) and an ultrasonic instrument (Varios 750, NSK, Tochigi, Japan) during 2 or more sessions completed within 42 days after the baseline visit [36]. Completeness of therapy was assessed by the study therapists and confirmed by a study dentist. During the treatment, the therapists provided oral hygiene
instructions, professional toothbrushing and mechanical tooth cleaning. Three and 6 months after the baseline visit, participants in the treatment group received periodontal maintenance therapy including oral hygiene instructions and oral prophylaxis for approximately 1 hour during a single session. Participants in the control group received only oral hygiene instructions at the baseline and 3 and 6 month visits. After the study completion, the control group participants received scaling and root planing.

Outcome assessment
The primary study outcome was the change in HbA1c levels from baseline to 3 months. Secondary outcomes included changes in oxidative stress balance, glycated albumin, QOL and clinical periodontal parameters from baseline to 3 months and baseline to 6 months. Change in diabetes medications at 3 and 6 months, and the need for periodontal rescue therapy and diabetes rescue therapy were evaluated as safety outcomes. A change in medication was defined as more than 2-fold change in dosage for a hyperglycemic drug, more than 10% change in dosage for insulin, or change in an oral hyperglycemic agent or insulin [35].

Sample size calculation
Sample size was estimated assuming a 0.8% (SD, 0.8%) or greater reduction in HbA1c levels from baseline to 3 months in the periodontal treatment group compared with the control group [37]. Based on the data, it was determined that 17 subjects per group would be necessary to provide an 80% power with an alpha of 0.05, 2-tailed and unpaired t test. Assuming an attrition rate of 15% [38], the planned sample size was 40 participants (20 in each treatment group).

Data collection
Data were collected by trained and certified study personnel. Study personnel recorded medical history, medication use, demographics, and lifestyle information including sex, age, height, weight, drinking habit, smoking habit, frequency of toothbrushing, use of interdental brush and also administered the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire [39]. The DTR-QOL includes 4 factors: "burden on social activities and daily activities" (factor 1), "anxiety and dissatisfaction with treatment" (factor 2), "hypoglycemia" (factor 3), and "satisfaction with treatment" (factor 4) [39].

Oral examination
The periodontal examiners (dentists) performed the following oral examination. PPD and CAL were determined at six sites (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual, mid-lingual and disto-lingual) on all teeth using a color-coded probe (CP-11 Color-Coded Probe, Hu-Friedy). Sites that bled upon gentle probing (25 g probing force) were recorded, and the proportion of sites with bleeding on probing (BOP) and the number of BOP-positive teeth were measured in each subject. Plaque Control Record was measured after erythrosine staining, and recorded with respect to their relative location to the gingival margin at four sites (mesial, distal, buccal and lingual) around each tooth [40]. All clinical procedures were performed by two calibrated dentists. To check the intra- and inter-examiner agreement, measurements of PPD and CAL were recorded and repeated within a 2-week interval in two randomly selected chronic periodontitis patients. Data were analyzed with the non-parametric κ test and intra-class correlation was determined. The κ coefficients for intra- and inter-examiner and intra-class correlation coefficients were >0.8.
Laboratory measures

At the clinical laboratory of Okayama University Hospital, venous blood samples were collected prior to periodontal measures or therapy. Fresh whole-blood samples were refrigerated and HbA1c levels were analyzed by high-performance liquid chromatography (Tosoh HLC-723G8, glycated hemoglobin analyzer, Tosoh Medics Inc., Tokyo, Japan). Serum samples were snap frozen and shipped on dry ice for analysis of levels of glycated albumin, lipids and creatinine by enzymatic methods using the automatic analyzer (JEOL BM 8040 and JCA-BM 6050, JEOL Ltd., Tokyo, Japan). High sensitive CRP was measured by an ELISA kit (High Sensitive Enzyme-Linked Immunosorbent Assay (ELISA) Kit for CRP, Cloud-Clone Corp., Houston, TX, USA). Levels of serum reactive oxygen metabolites (ROMs) (whole oxidant capacity of serum against N, N-diethylparaphenyldiamine in acidic buffer) were measured using a spectrophotometer (Diacron International, Grosseto, Italy), as reported previously [41]. Briefly, 20 μL serum samples were gently mixed with 1.2 mL acetate buffer (pH 4.8) in a cuvette, and 20 μL of chromogenic substrate (N, N-diethylparaphenyldiamine) was added. The cuvette was immediately incubated in the thermostatic block of the analyzer for 5 minutes at 37˚C. Absorbance at 505 nm was automatically recorded. The Carratelli unit (CARR U), where one CARR U corresponds to 0.08 mg/dL hydrogen peroxide, was used as the measurement unit. In order to determine total serum anti-oxidant capacity, data from the OXY-adsorbent test were collected using a spectrophotometer (Diacron International) [42]. This test evaluates the capacity of serum to oppose the massive oxidative action of a hypochlorous acid (HClO) solution. Briefly, 10 μL of standards or samples, previously diluted 1:100 with distilled water, were added and mixed with 1 mL of the HClO solution. After 10-min incubation at 37˚C, 10 μL of chromogenic mixture (solution provided in the kit) was added. Absorbance at 505 nm was measured immediately by the spectrophotometer. Total anti-oxidant capacity was expressed as micromoles of HClO consumed by 1 mL of sample (μmol HClO/mL). Furthermore, standardized values of the ROM and OXY-adsorbent tests were used to represent the Oxidative-INDEX as oxidative stress balance [43]. The Oxidative-INDEX was calculated by subtracting the OXY standardized variable from the ROM standardized variable. High Oxidative-INDEX values indicate high oxidative stress in the blood.

Adverse events and safety monitoring

Oral symptoms were recorded 2 weeks following periodontal treatment (periodontal treatment group) or baseline for the control group. There were no cases in which rescue therapy was administered to patients with acute changes in periodontitis. After the trial, patients were referred for follow-up periodontal care or additional treatment as needed.

Statistical analysis

Data analysis was performed using the Statistical Package for the Social Sciences (SPSS version 19, IBM, Tokyo, Japan). Data were summarized using means (± SDs) for continuous variables and frequencies (percentages) for categorical variables. We used an analysis of covariance (ANCOVA) for primary outcome and for secondary outcomes using the intention-to-treat analysis. The ANCOVA model included use of insulin, number of diabetes medication and HbA1c as covariate. Adjusted differences and 95% confidence intervals (CIs) were determined. P values were based on t-tests comparing mean changes between the control and periodontitis groups with Bonferroni’s method from ANCOVA. Missing data were managed according to the last observation carried forward analysis in accordance with the guidelines [44].

A per-protocol analysis based on data available both at baseline and the 3/6-month visits was also performed without imputation. Subgroup analyses were preplanned for HbA1c levels. In
the subgroup analysis, we focused on moderately poor glycemic control (HbA1c; 7.0 to 10.0%) [35, 45]. To check the attrition bias, we compared the baseline characteristics between retained and dropout groups using chi-squared test and t-test. The significance level was \( p < 0.05 \).

**Results**

**Retention of participants**

As shown in Fig 1, 46 individuals were screened and 40 were randomized between April 2014 and March 2016. When the number of participants reached 40, the recruitment was ended. Of the 40 randomized participants, 37 (92.5%) were included in the primary analysis, and 28 (70.0%) completed the study; retention in the periodontal treatment group was 15/20 and 13/20 in the control group. Baseline characteristics were similar between the two groups (Table 1).

**Primary outcome**

The target 3-month reduction of HbA1c levels of 0.8% or greater was not achieved. In the intention-to-treat analysis of the primary outcome, change in HbA1c levels at 3 months did
not differ significantly between the periodontal treatment and control groups (Table 2). A per-protocol analysis evaluating the change in HbA1c levels also did not reveal between-group differences at 3 months (S1 Table).

Secondary outcomes
A per-protocol analysis evaluating the change in HbA1c levels also did not reveal between-group differences at 6 months (S1 Table).

Table 1. Characteristics of participants at baseline.

| Parameter                              | Control group (N = 17) | Periodontal treatment group (N = 20) |
|----------------------------------------|------------------------|-------------------------------------|
| Sex                                    | Male                   |                                     |
| Age (years)                            | 62.8 ± 12.1\(^t\)      | 61.2 ± 9.2                           |
| Use of insulin                         | 8 (47.1)               | 6 (30.0)                            |
| Medical history except for diabetes (number) | 17 (100.0)          | 18 (90.0)                           |
| Medication except for diabetes (number) | 17 (100.0)           | 19 (95.0)                           |
| BMI (kg/m\(^2\))                       | 27.0 ± 4.4             | 25.4 ± 3.6                           |
| Exercise time (hour/week)              | 1.3 ± 2.7              | 2.3 ± 2.3                            |
| Smoker (person)                        | 5 (29.4)               | 2 (10.0)                             |
| Drinker (person)                       | 7 (41.2)               | 7 (35.0)                             |
| Frequency of toothbrushing (times/day) | ≥ two times            | 7 (41.2)                             |
| Use of interdental brush (number)      | 4 (23.5)               | 5 (25.0)                             |
| HbA1c (%)                              | 7.7 ± 1.2              | 7.5 ± 1.7                            |
| Glycated albumin (mg/dL)               | 19.3 ± 3.4             | 19.3 ± 4.7                           |
| Cr (mg/dL)                             | 1.0 ± 0.5              | 0.9 ± 0.3                            |
| TG (mg/dL)                             | 171.3 ± 91.1           | 165.6 ± 110.4                        |
| HDL-C (mg/dL)                          | 49.5 ± 13.3            | 55.9 ± 11.4                          |
| LDL-C (mg/dL)                          | 98.2 ± 19.5            | 95.4 ± 27.2                          |
| hs-CRP (ng/mL)                         | 4287.0 ± 1048.3        | 5153.3 ± 1780.2                      |
| Oxidative INDEX                       | Factor 1               | 61.4 ± 22.2                          |
|                                       | Factor 2               | 33.7 ± 11.3                          |
|                                       | Factor 3               | 19.2 ± 7.3                           |
|                                       | Factor 4               | 19.5 ± 5.0                           |
|                                       | Total                  | 133.8 ± 39.0                         |
| Number of teeth present               | 24.8 ± 4.8             | 24.3 ± 6.2                           |
| Mean PPD (mm)                          | 2.4 ± 0.7              | 2.4 ± 0.5                            |
| PD ≥ 4mm (%)                           | 25.2 ± 26.2            | 27.9 ± 28.4                          |
| Mean CAL (mm)                          | 2.7 ± 0.9              | 2.6 ± 0.6                            |
| CAL ≥ 4mm (%)                          | 32.5 ± 26.0            | 36.0 ± 25.2                          |
| BOP (%)                                | 23.1 ± 17.2            | 29.4 ± 21.4                          |
| PCR (%)                                | 48.4 ± 19.6            | 54.6 ± 19.8                          |

* N (%)
\(^t\) Mean±SD
HbA1c, hemoglobin A1c; Cr, serum creatinine; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; hs-CRP, high sensitive C-reactive protein; DTR-QOL, Diabetes Therapy-Related QOL; PPD, probing pocket depth; CAL, clinical attachment level; BOP, bleeding on probing; PCR, Plaque Control Record.

https://doi.org/10.1371/journal.pone.0188171.t001
Table 2. General conditions and periodontal parameters at follow-up in the primary analysis.

| Parameter                          | 3 months follow-up | 6 months follow-up |
|------------------------------------|--------------------|--------------------|
|                                    | Control group      | Periodontal treatment group | Adjusted difference (95% CI) | P value |
| HbA1c (%)                          | 7.7 ± 1.1 *        | 7.4 ± 1.4          | -0.16 (-0.56 to 0.23)        | 0.409   |
| Glycated albumin (mg/dL)           | 19.9 ± 3.8         | 19.5 ± 4.4         | -0.58 (-1.37 to 0.20)        | 0.140   |
| Oxidative INDEX                    | 0.2 ± 1.1          | -0.9 ± 1.6         | -1.19 (-2.03 to -0.35)       | 0.007   |
| DTR-QOL Factor 1                   | 99.6 ± 52.0        | 109.0 ± 40.6       | -0.99 (-31.37 to 29.39)      | 0.947   |
| Mean PPD (mm)                      | 2.5 ± 0.8          | 2.2 ± 0.6          | -0.27 (-0.47 to -0.07)       | 0.011   |
| PD ≥ 4mm (%)                       | 26.3 ± 29.6        | 20.5 ± 28.8        | -6.75 (-17.88 to 4.39)       | 0.226   |
| Mean CAL (mm)                      | 2.7 ± 1.0          | 2.4 ± 0.6          | -0.22 (-0.42 to -0.03)       | 0.024   |
| CAL ≥ 4mm (%)                      | 34.5 ± 29.5        | 28.5 ± 27.0        | -8.19 (-19.28 to 2.90)       | 0.142   |
| BOP (%)                            | 25.1 ± 16.7        | 24.1 ± 22.3        | -8.72 (-19.38 to 1.93)       | 0.105   |
| PCR (%)                            | 42.6 ± 22.6        | 39.6 ± 17.6        | -8.61 (-20.10 to 2.88)       | 0.137   |

(Continued)
In the intention-to-treat analysis of periodontal parameters, changes in mean PPD and mean CAL at 3 and 6 months significantly differed between the periodontal treatment and control groups (Table 2). Changes in the percentage of CAL ≥4mm and BOP significantly differed between the periodontal treatment and control groups at 6 months (Table 2).

In the intention-to-treat analysis of oxidative stress, changes in oxidative-INDEX significantly differed between the periodontal treatment and control groups at 3 months (Table 2). Results in the per-protocol analysis were also similar (S1 Table).

At 3 months, the change in factor 4 (satisfaction with treatment of diabetes) in DTR-QOL significantly differed between the periodontal treatment and control groups (Table 2). The result in the per-protocol analysis was also similar (S1 Table).

We also compared the baseline characteristics between retained and dropout groups. There were significant differences in some parameters between the retained and dropout groups (S2 Table).

Of the 30 participants with medication data available at all study visits, 14 of 15 (93.3%) in the periodontal treatment group and 13 of 15 (86.7%) in the control group had no protocol-defined changes in diabetes medications during the study.

### Sub-group analysis

Change in HbA1c levels at 3 months in the sub-group [moderately poor glycemic control (HbA1c; 7.0 to 10.0%)] tended to show the difference between the periodontal treatment and control groups but did not reach the significant level (P = 0.070) (Table 3). Changes in mean PPD at 3 and 6 months significantly differed between the periodontal treatment and control groups (Table 3). The results of counterpart were shown in the S3 Table.

### Harms

The non-surgical periodontal treatment was a low-risk study, and no study-related serious adverse events occurred in all patients. No patients in the two groups required generalized
Table 3. General conditions and periodontal parameters at baseline and follow-up in the sub-group analysis [moderately poor glycemic control (HbA1c: 7.0 to 10.0%)].

| Parameter                  | Baseline          | 3 months follow-up       |
|----------------------------|------------------|-------------------------|
|                            | Control group    | Periodontal treatment group | Adjusted difference† (95% CI) | P value‡ |
| HbA1c (%)                  | 8.1 ± 0.9*       | 7.8 ± 0.5               | -0.41 (-0.86 to 0.04)            | 0.070    |
| Glycated albumin (mg/dL)   | 20.0 ± 3.1       | 20.0 ± 3.0              | -0.90 (-2.33 to 0.54)            | 0.201    |
| Oxidative INDEX            | 0.4 ± 2.1        | -0.2 ± 1.4              | -0.50 (-1.99 to 0.99)            | 0.479    |
| DTR-QOL                    |                  |                         |                                       |
| Factor 1                   | 55.7 ± 23.8      | 63.4 ± 16.9             | 12.62 (-32.91 to 58.15)           | 0.560    |
| Factor 2                   | 30.8 ± 11.0      | 35.1 ± 12.7             | 1.30 (-7.67 to 5.08)              | 0.667    |
| Factor 3                   | 19.6 ± 7.5       | 20.7 ± 8.7              | -1.80 (-3.50 to 0.10)             | 0.058    |
| Factor 4                   | 17.3 ± 5.4       | 18.3 ± 7.7              | -1.30 (-4.50 to 1.90)             | 0.280    |
| Total                      | 123.4 ± 39.8     | 137.6 ± 38.3            | 17.28 (-32.77 to 67.33)           | 0.469    |
| Number of teeth present    | 26.3 ± 3.2       | 25.4 ± 2.6              | 0.34 (-0.43 to 1.11)              | 0.361    |
| Mean PPD (mm)              | 2.4 ± 0.8        | 2.5 ± 0.5               | -0.39 (-0.77 to -0.01)            | 0.046    |
| PD≥4mm (%)                 | 22.5 ± 26.5      | 34.4 ± 34.0             | -16.30 (-38.98 to 6.37)           | 0.144    |
| mean CAL (mm)              | 2.6 ± 1.0        | 2.8 ± 0.5               | 0.07 (-0.73 to 0.00)              | 0.050    |
| CAL≥4mm (%)                | 31.4 ± 27.4      | 45.5 ± 27.3             | 14.10 (-38.98 to 6.97)            | 0.201    |
| BOP (%)                    | 19.3 ± 16.1      | 29.8 ± 23.1             | 4.10 (-6.80 to 11.00)             | 0.058    |
| PCR (%)                    | 46.0 ± 23.3      | 47.4 ± 19.2             | 2.40 (-6.50 to 11.30)             | 0.046    |

(Continued)
periodontal rescue therapy during the study. In the control group, there were no patients who received the non-surgical periodontal treatment during the study.

Discussion

To the best of our knowledge, this study is the first randomized clinical trial to investigate the effects of non-surgical periodontal treatment on systemic oxidative stress balance, QOL and glycemic control in patients with T2DM and chronic periodontitis. Despite its effectiveness in improving clinical measures of periodontitis, the periodontal therapy did not significantly change HbA1c levels at 3 or 6 months in the periodontal treatment group, and no differences in changes in HbA1c levels were observed between the two groups. Findings were similar in the intention-to-treat and the per-protocol analyses. Likewise, the periodontal treatment had

Table 3. (Continued)

| Parameter                        | 6 months follow-up | Adjusted difference (95% CI) | P value |
|----------------------------------|--------------------|------------------------------|---------|
|                                  | Control group (N = 10) | Periodontal treatment group (N = 7) |             |         |
| HbA1c (%)                        | 8.1 ± 1.1          | 7.7 ± 0.5                    | 0.04 (-0.60 to 0.69) | 0.892   |
| Glycated albumin (mg/dL)         | 17.6 ± 6.6         | 20.8 ± 3.5                   | -1.25 (-9.11 to 6.61) | 0.637   |
| Oxidative INDEX                  | 0.7 ± 1.8          | 0.1 ± 1.3                    | -0.76 (-2.60 to 1.08) | 0.386   |
| DTR-QOL                          | Factor 1           | 55.1 ± 25.6                  | 16.66 (-15.76 to 49.08) | 0.287   |
|                                  | Factor 2           | 36.4 ± 13.1                  | 2.33 (-8.84 to 13.50) | 0.660   |
|                                  | Factor 3           | 18.8 ± 8.1                   | 0.43 (-7.00 to 7.86) | 0.903   |
|                                  | Factor 4           | 15.6 ± 3.9                   | 0.63 (-5.70 to 6.95) | 0.834   |
|                                  | Total              | 117.9 ± 52.6                 | 20.05 (-33.22 to 73.32) | 0.431   |
| Number of teeth present          | 25.9 ± 3.1         | 25.3 ± 2.7                   | 0.34 (-0.43 to 1.11) | 0.361   |
| Mean PPD (mm)                    | 2.5 ± 0.9          | 2.2 ± 0.7                    | -0.53 (-1.03 to -0.03) | 0.040   |
| PD ≥ 4mm (%)                     | 29.6 ± 32.6        | 24.3 ± 33.6                  | -17.43 (-41.54 to 6.67) | 0.142   |
| mean CAL (mm)                    | 2.9 ± 1.0          | 2.6 ± 0.5                    | 0.48 (-0.96 to -0.02) | 0.041   |
| CAL ≥ 4mm (%)                    | 40.1 ± 31.0        | 39.0 ± 29.2                  | -16.00 (-40.18 to 8.19) | 0.177   |
| BOP (%)                          | 28.0 ± 21.8        | 18.6 ± 18.1                  | -22.54 (-44.69 to -0.39) | 0.047   |
| PCR (%)                          | 39.0 ± 27.1        | 32.4 ± 13.4                  | -10.33 (-26.90 to 6.24) | 0.201   |

* Mean±SD
† Adjusted for insulin, medication and HbA1c
‡ Change in each parameter between the control and periodontitis group based on t-test from ANCOVA.
CI, Confidence interval; HbA1c, hemoglobin A1c; DTR-QOL, Diabetes Therapy-Related QOL; PPD, probing pocket depth; CAL, clinical attachment level; BOP, bleeding on probing; PCR, plaque control record.

https://doi.org/10.1371/journal.pone.0188171.t003
no significant effect on glycated albumin. The results were similar to the previous large scale randomized clinical trial [35]. However, systemic oxidative stress balance and QOL score (satisfaction with diabetes treatment) were improved by the treatment and there were significant differences between the two groups at 3 months. Systemic oxidative stress affects the pathophysiology of diabetes [46]. On the other hand, satisfaction with diabetes treatment contributes to compliance [39]. Thus, periodontal treatment may be considered in patients with T2DM for its benefits of improving pathophysiology and compliance.

The primary outcome of glycemic control in this study was in contrast with three recently published meta analyses that showed a modest and significant reduction in HbA1c levels following periodontal treatment (-0.36% [95% CI, -0.54% to -0.19%], p < 0.0001 [12]; -0.48% [95% CI, -0.78% to 0.18%, p = 0.002 [47]; -0.40% [95% CI, -0.78% to -0.01%), P = 0.04 [8].) Some features of the present study may account for these differences. First, our trial enrolled participants who were under the care of two physicians for their diabetes and were within a range of HbA1c values that would be less likely to trigger a change in medications during the study period. We monitored changes in hypoglycemic medications during the study period like the previous study [35]. The number of patients with changes in diabetes medications during the study was quite small and was similar between the two groups. This aspect of the study design was critical, because medications may have a profound short-term influence on HbA1c levels, a point not adequately documented in previous studies. Second, we did not exclude patients with extremely lower or higher HbA1c levels before randomization. As a review suggests that the variety of HbA1c level in a study population may influence the results [48], we performed the sub-group analysis. It showed a modest (-0.41% [95% CI, -0.86% to 0.04%], P = 0.070) but not significant reduction in HbA1c levels following periodontal treatment. The values were within the range of previous studies [8, 12, 47]. However, the result needs to be interpreted with caution because the number of subgroup was small. Finally, the degree of improved periodontal parameters may be small in this study. The mean difference in change in mean PPD between the periodontal treatment and control groups was -0.27mm (95% CI, -0.47mm to -0.07mm, P = 0.011) at 3 months follow-up. In the meta-analysis, the mean difference was -0.39 mm (95% CI, -0.64 mm to -0.15 mm) after 3–4 months follow-up [8].

As a second outcome, we focused on systemic oxidative stress balance. Oxidative stress plays an important role in the pathophysiology of both periodontal disease and T2DM [15–25]. Oxidative stress appears to be important in the development and progression of diabetic complications [49]. For example, acute glucose variability induces endothelial dysfunction through oxidative stress, which can cause atherosclerosis [50]. On the other hand, periodontal treatment itself and adjunctive therapy for traditional periodontal treatment using antioxidant agents can improve systemic oxidative stress [24, 26, 51, 52]. The improvement of oxidative stress may contribute to improving glycemic control and reducing diabetes complications [53–56]. In this study, there were significant differences in the change in oxidative stress balance between the periodontal treatment and control groups at 3 months. However, the effects of periodontal treatment were transient. Long term effects on oxidative stress balance as well as glycemic control remain an issue [35].

Diabetes and its complications impair patients’ QOL [28, 30]. Improvement of these complications, e.g., periodontitis, may contribute to better QOL for diabetes patients. We reported that QOL scores (satisfaction with diabetes treatment) were improved following periodontal treatment. Treatment satisfaction influences compliance [39], which may contribute to the management of both diabetes and periodontitis. Thus, we have evaluated this new aspect in the present study, as recent reviews suggest that outcome measures in clinical trials should include QOL [9, 32]. However, the effect in this study was observed at 3 months, but not at 6
months. Further studies are needed to elucidate the factors involved in improving treatment compliance.

Patient characteristics were similar to other trials and were not population-specific. In this study, parameters such as age, HbA1c level, mean PPD, and mean CAL at baseline were within the range of the previous studies, which were similar with our design [35, 37, 57].

This study has some limitations. First, the sample size was determined by the previous study [37] but not the systemic reviews. Second, the non-surgical periodontal treatment was performed by general dentists, not periodontists. Since general dentists can play an important role in the community from the viewpoint of public health, we did not choose periodontists for this study. These factors may underestimate the treatment effects. Third, not all of the clinical parameters were improved following periodontal treatment. Although PPD, CAL and BOP were significantly improved in the periodontal treatment group, significant improvement of PCR scores was not observed, indicating that changing self-care remains a challenge in T2DM patients.

Our trial, meanwhile, has a number of strengths. First, changes in diabetes medications were monitored during the follow-up visits. Second, periodontal treatment was conducted under supervision and resulted in a positive effect on a clinical measure of periodontitis among participants in the periodontal treatment group. Finally, the core laboratory responsible for the centralized analysis of blood samples analyzed the HbA1c values in a blinded manner.

**Conclusion**

In T2DM patients, non-surgical periodontal treatment improved systemic oxidative stress balance and QOL, but did not decrease the levels of HbA1c as the main outcome at 3 months follow-up.

**Supporting information**

S1 Table. General conditions and periodontal parameters at baseline and follow-up in the per-protocol analysis.

(SDOCX)

S2 Table. Differences between the retained and dropout groups at baseline.

(SDOCX)

S3 Table. General conditions and periodontal parameters at baseline and follow-up in the sub-group analysis except for moderately poor glycemic control group.

(SDOCX)

S4 Table. CONSORT checklist.

(SDOC)

S1 Protocol. Protocol (in Japanese).

(SDOC)

S2 Protocol. Protocol (in English).

(SDOC)

**Acknowledgments**

The authors are grateful to Prof. Keiki Ogino, Dr. Eri Eguchi, Dr. Kenjiro Nagaoka, Dr. Narumi Funakubo, Dr. Zhang Ran and Dr. Masayuki Kubo (Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences...
Okayama, Japan), Yuya Kawabata (Kawabata Dental Clinic, Hiroshima, Japan) and Dr. Shin-suke Mizutani (Section of Geriatric Dentistry, Department of General Dentistry, Fukuoka Dental College, Fukuoka, Japan) for their technical advice.

**Author Contributions**

**Data curation:** Takayuki Maruyama, Daiki Fukuhara, Yoshio Sugiura, Jun Wada.

**Formal analysis:** Takayuki Maruyama.

**Funding acquisition:** Takaaki Tomofuji, Manabu Morita.

**Investigation:** Kota Kataoka, Toshiki Yoneda.

**Methodology:** Takayuki Maruyama.

**Project administration:** Manabu Morita.

**Supervision:** Manabu Morita.

**Writing – original draft:** Hirofumi Mizuno.

**Writing – review & editing:** Hirofumi Mizuno, Daisuke Ekuni, Takayuki Maruyama, Kota Kataoka, Toshiki Yoneda, Daiki Fukuhara, Yoshio Sugiura, Takaaki Tomofuji, Jun Wada, Manabu Morita.

**References**

1. Guideline Committee of the Japan Diabetes Society. Japan Diabetes Society evidence-based practice guidelines for the treatment of diabetes in Japan. 2016. http://www.fa.kyorin.co.jp/jds/uploads/GL2016-02.pdf. Cited 12 February 2017.

2. American Diabetes Association. 3. Foundations of Care and Comprehensive Medical Evaluation. Diabetes Care. 2016; 39: S23–S35. https://doi.org/10.2337/dc16-S006 PMID: 26696676

3. Löe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care. 1993; 16: 329–334. PMID: 8422804

4. Hirschfeld L, Wasserman B. Along-termsurvey of tooth loss in 600 treated periodontal patients. J Periodontol. 1978; 49: 225–237. https://doi.org/10.1902/jop.1978.49.5.225 PMID: 277674

5. Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol. 2011; 7: 738–748. https://doi.org/10.1038/nrendo.2011.106 PMID: 21709707

6. TEEw WJ, Gerdes VE, Loos BG. Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysis. Diabetes Care. 2010; 33: 421–427. https://doi.org/10.2337/dc09-1378 PMID: 20135557

7. Wang X, Han X, Guo X, Luo X, Wang D. The effect of periodontal treatment on hemoglobin a1c levels of diabetic patients: a systematic review and meta-analysis. PLoS One. 2014; 9: e108412. https://doi.org/10.1371/journal.pone.0108412 PMID: 25255331

8. Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev. 2013; 12: CD004714.

9. Simpson TC, Weldon JC, Worthington HV, Needleman I, Wild SH, Moles DR, et al. Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev. 2015; 6: CD004714.

10. Casanova L, Hughes FJ, Preshaw PM. Diabetes and periodontal disease: a two-way relationship. Br Dent J. 2014; 217: 433–437. https://doi.org/10.1038/bdj.2014.907 PMID: 25342350

11. Borgnakke WS, Ylöstalo PV, Taylor GW, Genco RJ. Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. J Periodontol. 2013; 84: S135–S152. https://doi.org/10.1902/jop.2013.1340013 PMID: 23631574

12. Engebretson S, Kocher T. Evidence that periodontal treatment improves diabetes outcomes: a systematic review and meta-analysis. J Periodontol. 2013; 84: S153–S169. https://doi.org/10.1902/jop.2013.1340017 PMID: 23631575
13. Liew AK, Punnanithinont N, Lee YC, Yang J. Effect of non-surgical periodontal treatment on HbA1c: a meta-analysis of randomized controlled trials. Aust Dent J. 2013; 58: 350–357. https://doi.org/10.1111/adj.12091 PMID: 23981218

14. Darré L, Vergnes JN, Gourdy P, Sixou M. Efficacy of periodontal treatment on glycaemic control in diabetic patients: A meta-analysis of interventional studies. Diabetes Metab. 2008; 34: 497–506. https://doi.org/10.1016/j.diabet.2008.03.006 PMID: 18948050

15. Reddy PV, Ambati M, Kodugant R. Systemic lycopene as an adjunct to scaling and root planing in chronic periodontitis patients with type 2 diabetes mellitus. J Int Soc Prev Community Dent. 2015; 5: S25–S31. https://doi.org/10.4103/2231-0762.156520 PMID: 25984464

16. Dandonia P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, et al. Oxidative damage to DNA in diabetes mellitus. Lancet. 1996; 347: 444–445. PMID: 8618487

17. Urakawa H, Katsuki A, Sumida Y, Gabazza EC, Murashima S, Morio K, et al. Oxidative stress is associated with adiposity and insulin resistance in men. J Clin Endocrinol Metab. 2003; 88: 4673–4676. https://doi.org/10.1210/jc.2003-030202 PMID: 14557439

18. Borges I Jr, Moreira EA, Filho DW, de Oliveira TB, da Silva MB, Fröde TS. Proinflammatory and oxidative stress markers in patients with periodontal disease. Mediators Inflamm. 2007; 2007: 45794. https://doi.org/10.1155/2007/45794 PMID: 18288271

19. Chapple IL, Matthews JB. The role of reactive oxygen and antioxidant species in periodontal tissue destruction. Periodontology 2000. 2007; 43: 160–232. https://doi.org/10.1111/j.1600-0757.2006.00178.x PMID: 17214840

20. Panjamberthy K, Manoharan S, Ramachandran CR. Lipid peroxidation and antioxidant status in patients with periodontitis. Cell Mol Biol Lett. 2005; 10: 255–264. PMID: 16010291

21. Su H, Gomitsky M, Velly AM, Yu H, Benaroch M, Schipper HM. Salivary DNA, lipid, and protein oxidation in nonsmokers with periodontal disease. Free Radic Biol Med. 2009; 46: 914–921. PMID: 19280702

22. Takane M, Sugano N, Iwasaki H, Iwano Y, Shimizu N, Ito K. New biomarker evidence of oxidative DNA damage in whole saliva from clinically healthy and periodontally diseased individuals. J Periodontol. 2002; 73: 551–554. https://doi.org/10.1902/jop.2002.73.5.551 PMID: 12027259

23. Kajiyama S, Hasegawa G, Asano M, Hosoda H, Fukui M, Nakamura N, et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr Res. 2008; 28: 137–143. https://doi.org/10.1016/j.nutres.2008.01.008 PMID: 19083400

24. Bullon P, Newman HN, Battino M. Obesity, diabetes mellitus, atherosclerosis and chronic periodontitis: a shared pathology via oxidative stress and mitochondrial dysfunction? Periodontol 2000. 2014; 64: 139–153. https://doi.org/10.1111/j.1600-0757.2012.00455.x PMID: 24320961

25. Nowotny K, Jung T, Höhn A, Weber D, Grune T. Advanced glycation end products and oxidative stress in type 2 diabetes mellitus. Biomolecules. 2015; 5: 194–222. https://doi.org/10.3390/biom5010194 PMID: 25786107

26. Tamaki N, Tomofuji T, Ekuni D, Yamana R, Morita M. Periodontal treatment decreases plasma oxidized LDL level and oxidative stress. Clin Oral Investig. 2011; 15: 953–958. https://doi.org/10.1007/s00784-010-0458-y PMID: 20717698

27. Chapple IL, Genco R; working group 2 of the joint EFP/AAP workshop. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol. 2013; 84: S106–S112. https://doi.org/10.1902/jop.2013.1340011 PMID: 23631572

28. Nezu S, Okamoto N, Morikawa M, Saeki K, Obayashi K, Tomioka K, et al. Health-related Quality of Life (HRQOL) Health-related quality of life (HRQOL) decreases independently of chronic conditions and geriatric syndromes in older adults with diabetes: the Fujiwara-kyo Study, J Epidemiol. 2014; 24: 259–266. https://doi.org/10.2188/jea.JE20130131 PMID: 24814506

29. Rombopoulos G, Hatzikou M, Latsou D, Yfantopoulos J. The prevalence of hypoglycemia and its impact on the quality of life (QoL) of type 2 diabetes mellitus patients (The HYPO Study). Hormones (Athens). 2013; 12: 550–558.

30. Alcubierre N, Rubinat E, Traveset A, Martinez-Alonso M, Hernandez M, Jurjo C, et al. A prospective cross-sectional study on quality of life and treatment satisfaction in type 2 diabetic patients with retinopathy without other major late diabetic complications. Health Qual Life Outcomes. 2014; 12: 131. https://doi.org/10.1186/s12955-014-0131-2 PMID: 25138117

31. Kisa K, Kawabata H, Itou T, Nishimoto N, Maezawa M. Survey of patient and physician satisfaction regarding patient-centered outpatient consultations in Japan. Intern Med. 2011; 50: 1403–1408. PMID: 21720060
32. Santos CM, Lira-Junior R, Fischer RG, Santos AP, Oliveira BH. Systemic Antibiotics in Periodontal Treatment of Diabetic Patients: A Systematic Review. PLoS One. 2015; 10: e0145262. https://doi.org/10.1371/journal.pone.0145262. PMID: 26693909
33. Miranda TS, Feres M, Perez-Chaparro PJ, Faveri M, Figueiredo LC, Tamashiro NS, et al. Metronidazole and amoxicillin as adjuncts to scaling and root planing for the treatment of type 2 diabetic subjects with periodontitis: 1-year outcomes of a randomized placebo-controlled clinical trial. J Clin Periodontol. 2014; 41: 890–899. https://doi.org/10.1111/jcpe.12262. PMID: 24930639
34. Eke PI, Page RC, Wei L, Thornton-Evans G, Genco RJ. Update of the case definitions for population-based surveillance of periodontitis. J Periodontol. 2012; 83: 1449–1454. https://doi.org/10.1902/jop.2012.110664. PMID: 22420873
35. Engebretson SP, Hyman LG, Michalowicz BS, Schoenfeld ER, Gelato MC, Hou W, et al. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized clinical trial. JAMA. 2013; 310: 2523–2532. https://doi.org/10.1001/jama.2013.282431. PMID: 24346989
36. DPTT study group., Engebretson S, Gelato M, Hyman L, Michalowicz BS, Schoenfeld E. Design features of the Diabetes and Periodontal Therapy Trial (DPTT): a multicenter randomized single-masked clinical trial testing the effect of nonsurgical periodontal therapy on glycosylated hemoglobin (HbA1c) levels in subjects with type 2 diabetes and chronic periodontitis. Contemp Clin Trials. 2013; 36: 516–526. https://doi.org/10.1016/j.cct.2013.09.010. PMID: 24080100
37. Kiran M, Arpak N, Unsal E, Erdoğan MF. The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus. J Clin Periodontol. 2005; 32: 266–272. https://doi.org/10.1111/j.1600-051X.2005.00658.x. PMID: 15766369
38. Santos VR, Lima JA, Miranda TS, Gonçalves TE, Faveri M, et al. Full-mouth disinfection as a therapeutic protocol for type-2 diabetic subjects with chronic periodontitis: twelve-month clinical outcomes: a randomized controlled clinical trial. J Clin Periodontol. 2013; 40: 155–162. https://doi.org/10.1111/jcpe.12040. PMID: 23305133
39. Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. J Med Econ. 2012; 15: 556–563. https://doi.org/10.3111/13696998.2012.665111. PMID: 22313327
40. O’Leary T.J.; Drake R.B.; Naylor J.E. The plaque control record. J Periodontol. 1972; 43: 38. https://doi.org/10.1902/jop.1972.43.1.38. PMID: 4500182
41. Tamaki N, Tomofuji T, Ekuni D, Yamakawa R, Yamamoto T, Morita M. Short-term effects of nonsurgical periodontal treatment on plasma level of reactive oxygen metabolites in patients with chronic periodontitis. J Periodontol. 2009; 80: 901–906. https://doi.org/10.1902/jop.2009.080640. PMID: 19485819
42. Terao M, Takaki A, Maruyama T, Oe H, Yasunaka T, Tamaki N, et al. Serum Oxidative/anti-oxidative Stress Balance Is Dysregulated in Potentially Pulmonary Hypertensive Patients with Liver Cirrhosis: A Case Control Study. Intern Med. 2015; 54: 2815–2826. https://doi.org/10.2169/internalmedicine.54.526. https://doi.org/10.1016/j.fertnstert.2011.11.045. PMID: 24346989
43. Casarin RC, Duarte PM, Santos VR, Lima JA, Gagnon G, Casati MZ, et al. Influence of glycemic control on Epstein-Bar and Cytomegalovirus infection in periodontal pocket of type 2 diabetic subjects. Arch Oral Biol. 2010; 55: 902–906. https://doi.org/10.1016/j.archoralbio.2010.07.009. PMID: 20728869
44. Badger JK, Hartley B, Halterman JS, Jellinck P, Gisondi J, Reisig J, et al. Full-mouth debridement and systemic antibiotics for the treatment of diabetic periodontitis: 1-year outcomes of a randomized placebo-controlled clinical trial. J Clin Periodontol. 2014; 41: 890–899. https://doi.org/10.1111/jcpe.12262. PMID: 24930639
45. Vassalle C, Sciarrino R, Bianchi S, Battaglia D, Mercuri A, Maffei S. Sex-related differences in association of oxidative stress status with coronary artery disease. Fertil Steril. 2012; 97: 414–419. https://doi.org/10.1016/j.fertnstert.2011.11.045. PMID: 22196713
46. Committe for Medicinal Products for Human Use (CHMP). Guideline on Missing Data in Confirmatory Clinical Trials. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf. Cited 12 February 2017.
47. Care. 1996; 19: 257–267. PMID: 8742574
48. Borgnakke WS, Chapelle IL, Genco RJ, Armitage G, Bartold PM, D’Aiuto F, et al. The multi-center randomized controlled trial (RCT) published by the journal of the American Medical Association (JAMA) on the effect of periodontal therapy on glycedated hemoglobin (HbA1c) has fundamental problems. J Evid Based Dent Pract. 2014; 14: 127–132.
49. Giugliano D, Criello A, Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care. 1996; 19: 257–267. PMID: 8742574
50. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008; 57: 1349–1354. https://doi.org/10.2337/db08-0063 PMID: 18299315

51. Azuma T, Yamane M, Ekuni D, Kawabata Y, Kataoka K, Kasuyama K, et al. Drinking hydrogen-rich water has additive effects on non-surgical periodontal treatment of improving periodontitis: A pilot study. Antioxidants (Basel). 2015; 4: 513–522.

52. Muniz FW, Nogueira SB, Mendes FL, Rösing CK, Moreira MM, de Andrade GM, et al. The impact of antioxidant agents complimentary to periodontal therapy on oxidative stress and periodontal outcomes: A systematic review. Arch Oral Biol. 2015; 60: 1203–1214. https://doi.org/10.1016/j.archoralbio.2015.05.007 PMID: 26067357

53. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol. 2003; 14: S250–S253. PMID: 12874441

54. van Dam PS, Bravenboer B, van Asbeck BS, Marx JJ, Gispen WH. High rat food vitamin E content improves nerve function in streptozotocin-diabetic rats. Eur J Pharmacol. 1999; 376: 217–22. PMID: 10448879

55. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes. 2001; 50: 1938–1942. PMID: 11473058

56. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006; 440: 944–948. https://doi.org/10.1038/nature04634 PMID: 16612386

57. Telgi RL, Tandon V, Tangade PS, Tirth A, Kumar S, Yadav V. Efficacy of nonsurgical periodontal therapy on glycaemic control in type II diabetic patients: a randomized controlled clinical trial. J Periodontal Implant Sci. 2013; 43: 177–182. https://doi.org/10.5051/jpis.2013.43.4.177 PMID: 24040570